Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in France / NCT07526220
Starting soon Observational

Prognostic Factors in Critically Ill Patients Admitted After Caustic Ingestion in France

NCT07526220 · tracked via the Priya Life Science France tracker
Sponsor
Société Française d'Anesthésie et de Réanimation
Phase
Observational
Started
2026-04-15
Last updated
2026-04-13

Condition(s) studied

Poisoning

Investigational drug(s) / intervention(s)

observationnal

observationnal: No intervention / data collection only

Study summary

DATACAUSTIC is a national retrospective multicentre observational study designed to identify prognostic factors associated with outcomes in critically ill adult patients admitted after caustic ingestion in France.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * age 18 years or older; * admission to a critical care unit for caustic ingestion within 72 hours; * no opposition to participation/data collection Exclusion Criteria: * Refus de participer à la recherche * Ingestion de caustique ne nécessitant pas une prise en charge en soins critiques

Primary outcome measure(s)

  • 1-year mortality — 1 year
    All-cause mortality at 1 year after admission to critical care for caustic ingestion

Trial sites (1)

FacilityCityRegionStatus
Hopital Saint louis Paris France

More Société Française d'Anesthésie et de Réanimation trials in France

Impact of Implementing a National Classification of Surgical Emergencies on Postoperative Morbidity and Mortality: a Prospective Multicenter Observational Study After Implementation. Starting soon
ICU Management of Brain-Dead Donors Before Multi-Organ Procurement and Factors Associated With the Number of Organs Retrieved Recruiting
Cangrelor As Treatment for Cardiac Surgery Associated With Heparin Induced Thrombocytopenia Starting soon
Perioperative Hemostasis Management in Liver Transplantation Recruiting
Diagnosis and Treatment of Late Neurological Ischemic Deficit in Patients Suffering From Subarachnoid Hemorrhage. Starting soon

Other trials for the same condition

Effectiveness of Environmental Measures to Eliminate the Risks of Lead Exposure in Infant Lead Poisoning Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07526220 on ClinicalTrials.gov ↗ ← All trials in France